<DOC>
	<DOC>NCT00696072</DOC>
	<brief_summary>The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone</brief_summary>
	<brief_title>Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Has histologic or cytologic diagnosis of breast cancer; evidence of unresectable locally recurrent or metastatic disease Has measurable or evaluableonly disease Is female, â‰¥18 yrs of age, post menopausal or surgically sterile HER2 negative, HR+, ER+ and/or PgR+ breast cancer 01 prior chemotherapy regimen for metastatic disease. Prior adjuvant or neoadjuvant chemotherapy completed at least 1 month prior Prior tamoxifen therapy is allowed No AI therapy for &gt;1 year without recurrence Pregnant or breast feeding Prior hormonal therapy for metastatic or locally recurrent disease &gt;1 chemotherapy regimen for metastatic disease Pleural or pericardial effusion Serious cardiac condition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>